Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
119 hedge funds and large institutions have $1.32B invested in Turning Point Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 23 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
1% less funds holding
Funds holding: 120 → 119 (-1)
25% less capital invested
Capital invested by funds: $1.76B → $1.32B (-$432M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26% less call options, than puts
Call options by funds: $1.2M | Put options by funds: $1.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$82.3M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$16.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$16.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$13.8M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$9.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$29.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.8M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$21.2M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18M |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$17.8M |
TPTX Hedge Fund Activity: Q1 2020 in Review
119 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q1 2020, worth a combined $1.32B — down 25% from $1.76B a quarter earlier.
Fund positioning in TPTX was balanced in Q1 2020: 23 funds opened new positions, 23 closed out, 46 added to existing stakes and 34 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $82.3M. The largest seller was venBio Partners, cutting an estimated $29.1M.
- 119 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q1 2020, down from 120 in Q4 2019.
- Funds reported $1.32B of Turning Point Therapeutics, Inc. Common Stock stock for Q1 2020, down 25% quarter-over-quarter.
- 23 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q1 2020 and 23 closed out, a net change of 0 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q1 2020 was Wellington Management Group, an estimated $82.3M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q1 2020 was venBio Partners, an estimated $29.1M sold.
Based on aggregated 13F filings for Q1 2020.